Researchers examined seven patients who were admitted to an interdisciplinary medical intensive care unit at a university hospital in southern Germany. All patients had been exposed to metamizole, a medication used for pain relief, before developing severe blood problems known as agranulocytosis.
The study found that two of the seven patients died from multiorgan failure. Among the five survivors, hospital stays were much longer than usual, ranging from 11 to 60 days. Survivors also experienced serious complications, including septic shock, acute respiratory distress syndrome, and kidney failure that required dialysis.
These findings highlight the potential severity of agranulocytosis caused by metamizole. However, because the study was a small, descriptive review of only seven cases at one hospital, it cannot tell us how often this happens in the general population. Readers should understand that while the risk is real and life-threatening, the absolute number of cases is low compared to how widely the drug is used. Careful benefit-risk assessment and considering alternative pain treatments remain essential for safe use.
